Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data

In conclusion, there were no clinically relevant interactions between NETU and PALO, or NEPA and oral contraceptives (based on levonorgestrel and ethinylestradiol exposure). Coadministration of NETU or NEPA with CYP3A4 inducers/inhibitors/substrates should be done with caution. Dose reduction is recommended for DEX. Dose adjustments are not needed for NETU coadministration with P-gp substrates.

Source: Journal of Oncology Pharmacy Practice - April 21, 2016 Category: Cancer & Oncology Authors: Natale, J. J., Spinelli, T., Calcagnile, S., Lanzarotti, C., Rossi, G., Cox, D., Kashef, K. Tags: Review Articles Source Type: research